CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene.
Atypical expression of CD44 splice variants has been implicated in the progression of numerous tumors. This abnormal CD44 expression is presumed to result from gene alterations that cause tumorigenic transformation. Two tumor types that have been linked to specific gene alterations are schwannomas, which have mutations in the neurofibromatosis (NF) type 2 (NF2) gene, and neurofibromas, which characteristically possess NF type 1 (NF1) gene mutations. We examined CD44 expression in normal sciatic nerves, in schwannomas with confirmed NF2 mutations, and in neurofibromas and malignant peripheral nerve sheath tumor tissue and cell lines from NF1 patients. Compared to normal nerves, schwannomas express higher total levels of CD44 and additional splice variants, whereas CD44 expression in neurofibromas is unaltered. Malignant peripheral nerve sheath tumor tissue and cell lines express the CD44v6 epitope, which is not expressed by normal Schwann cells or by other Schwann cell tumors. These data indicate that altered CD44 expression correlates strictly with mutations in the NF2 but not NF1 gene and suggest that CD44v6 might be a marker for the malignant transformation of Schwann cells.
Sherman
L
L
Forschungszentrum Karlsruhe, Institut für Genetik, Karlsruhe, Germany.
Jacoby
L B
LB
Lampe
J
J
Pelton
P
P
Aguzzi
A
A
Herrlich
P
P
Ponta
H
H
D017398:Alternative Splicing; D016514:Genes, Neurofibromatosis 1 / Q000235:genetics*; D016515:Genes, Neurofibromatosis 2 / Q000235:genetics*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D009442:Neurilemmoma / Q000235:genetics* / Q000378:metabolism*; D009455:Neurofibroma / Q000235:genetics* / Q000378:metabolism*; D017933:Peripheral Nervous System / Q000378:metabolism; D012583:Schwann Cells / Q000378:metabolism*
D018960:Hyaluronan Receptors; D009363:Neoplasm Proteins